Modification of the effects of estrogen therapy on HDL cholesterol levels by polymorphisms of the HDL-C receptor, SR-BI: the Rancho Bernardo Study.

Published

Journal Article

BACKGROUND: Previous studies have found polymorphisms of the HDL receptor, SR-BI, to be associated with plasma HDL-C in women, but not men, suggesting a modifying role of estrogen. We examined whether the association between SR-BI genotypes and HDL-C is modified by use of unopposed estrogen in community-dwelling postmenopausal Caucasian women. METHODS: Common polymorphisms in Intron5 and Exon8 of the SR-BI gene were evaluated in 689 women from the Rancho Bernardo Study. Multiple linear regression analysis was carried out adjusting for confounders. RESULTS: HDL-C levels did not differ significantly by genotype in the aggregate population. However, significant interaction was found between estrogen use and Exon8 (p=0.03), Intron5 (p=0.03) and Intron5/Exon8 diplotypes (p=0.01). SR-BI genotype was associated with HDL-C levels only among estrogen users (p=0.05) and explained 5.3% of the variance in HDL-C in this group. Consistent with prior studies, individuals heterozygous at both Intron5 and Exon8 loci had the lowest HDL-C levels. Among women with symptomatic CHD, the interaction between estrogen use and SR-BI genotype became even stronger. CONCLUSIONS: The effect that unopposed estrogen use has on HDL-C may depend on a woman's SR-BI genotype.

Full Text

Duke Authors

Cited Authors

  • Richard, E; von Muhlen, D; Barrett-Connor, E; Alcaraz, J; Davis, R; McCarthy, JJ

Published Date

  • June 2005

Published In

Volume / Issue

  • 180 / 2

Start / End Page

  • 255 - 262

PubMed ID

  • 15910850

Pubmed Central ID

  • 15910850

International Standard Serial Number (ISSN)

  • 0021-9150

Digital Object Identifier (DOI)

  • 10.1016/j.atherosclerosis.2004.12.013

Language

  • eng

Conference Location

  • Ireland